ARWR vs UNH

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...